Alumis (NASDAQ:ALMS) CFO John Schroer Sells 3,282 Shares

Alumis Inc. (NASDAQ:ALMS) CFO John Schroer sold 3,282 shares of Alumis stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $86,546.34. Following the completion of the sale, the chief financial officer directly owned 24,718 shares of the company’s stock, valued at $651,813.66. The trade was a 11.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Alumis Stock Performance

ALMS opened at $27.12 on Thursday. The stock’s 50-day moving average price is $25.37 and its 200 day moving average price is $25.22. Alumis Inc. has a 12-month low of $3.76 and a 12-month high of $31.35. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -13.70 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last released its earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.01). The firm had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. On average, research analysts forecast that Alumis Inc. will post -2.87 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on ALMS. Wells Fargo & Company increased their target price on shares of Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Citigroup restated a “buy” rating on shares of Alumis in a research note on Tuesday, May 19th. Morgan Stanley reaffirmed an “overweight” rating and set a $39.00 price objective on shares of Alumis in a research report on Friday, May 15th. HC Wainwright reiterated a “neutral” rating and issued a $25.00 price objective on shares of Alumis in a research note on Monday. Finally, Wall Street Zen lowered Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.30.

Institutional Trading of Alumis

Hedge funds have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB purchased a new position in Alumis in the second quarter worth approximately $1,024,000. Stempoint Capital LP purchased a new stake in shares of Alumis in the 1st quarter valued at approximately $5,057,000. Janus Henderson Group PLC acquired a new stake in shares of Alumis in the 1st quarter valued at $46,790,000. Ally Bridge Group NY LLC acquired a new stake in shares of Alumis in the 1st quarter valued at $3,678,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Alumis by 600.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company’s stock worth $69,000 after purchasing an additional 2,684 shares during the last quarter.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Neutral Sentiment: HC Wainwright reaffirmed its “Neutral” rating on Alumis, indicating the analyst does not currently see a strong enough catalyst to support a more bullish view. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six company insiders, including CFO John R. Schroer, sold a combined 14,953 shares of Alumis on August 3 at an average price of $26.37, generating approximately $394,311 in proceeds. The sales reduced individual holdings by roughly 1.28% to 12.28%; the CFO’s position declined 11.72%. While insider sales can reflect personal financial planning rather than a change in business outlook, the concentration of sales may weigh on investor sentiment. The transactions were reported in SEC filings for Read More., Read More., Read More., Read More., Read More., and Read More..

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.